Skip to content
etf.net

Launched · SEC filings

Tema Heart & Health ETF

HRTSNasdaqTemaD

$38.77−0.11 (−0.28%)

At close: Nov 2, 2026, 4:00 PM ET

D31/ 100

Rank 20 of 25 in Health Care (Broad)

D31/100Rank 20 of 25inHealth Care (Broad)
Intraday session: down, 79 prints from 38.87 to 38.77. Range 38.60 to 38.93. Use the arrow keys to read each point.38.6038.6538.7010 AM12 PM2 PM4 PM
Expense ratio
0.75%*
Fund size
$58M
1Y total return
+20.6%
Yield · Last 12 months
1.22%
Holdings
47
Avg volume · 30D
3.94K sh
52W range
low $32.00high $39.03
Launched
Filings
SEC EDGAR

*After a fee waiver that ends Jun 28, 2027. Without it: 0.99%.

The ETF.net HRTS Grade

D

Score 31 out of 100

Category
Health Care (Broad)⁠
Rank
20 of 25
Six-pillar profile for HRTS. Scores out of 100: Cost 8, Risk 52, Mission 73, Tradability 36, Holdings 65, Durability 37. Strongest: Mission (73). Weakest: Cost (8). Leans toward Mission.

Score 31 of 100 falls in the D band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    F8 out of 100
    Rank 22 of 25

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    A73 out of 100
    Rank 7 of 11

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    C52 out of 100
    Rank 12 of 25

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    D36 out of 100
    Rank 16 of 25

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    B65 out of 100
    Rank 12 of 25

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    D37 out of 100
    Rank 19 of 25

Our read on HRTS

ETF.net Research

In short

DBroad health care funds own insurers, hospitals and dental supply. HRTS narrows to one battlefield: heart and metabolic disease, with at least 80% of assets in companies earning half their revenue there.

Stated mandate

The Fund seeks long-term growth of capital and invests at least 80% of its assets in publicly listed companies deriving at least half of their revenue from cardiovascular- or metabolic-disease treatments.

Why people hold it

  • Written into the prospectus: at least 80% of assets in companies drawing half or more of their revenue from cardiovascular or metabolic disease treatment. Theme drift has a floor.
  • About 50 stocks picked by a manager rather than copied from an index, so the portfolio can follow the science instead of waiting on a benchmark reconstitution.
  • Nothing exotic under the hood: a plain 1940 Act fund holding listed stocks. No leverage sleeve, no derivatives wrapper to decode.

Worth knowing

  • 0.75% net of a waiver through June 28, 2027 (0.99% gross). That sits above the category median and well above broad peers like XLV at 0.08% or VHT at 0.09%.
  • One of the thinner traders in its category and smaller by assets. Limit orders matter more here than with a mega sector fund.
  • About 50 names in one disease niche: a single trial readout can move the whole portfolio. Concentration cuts both ways.

HRTS Performance

Launched Nov 20, 2023

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.Not enough history yet.Not enough history yet.
HRTS$12,061
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,146
Oct 31, 2025 to Nov 2, 2026. HRTS $12,061. SPY $11,146. Use the arrow keys to read each point.$10,000$11,000$12,000Oct 2025May 2026Nov 2026

Oct 31, 2025 – Nov 2, 2026

Returns run to the Nov 2, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for HRTS. Periods over one year show the average yearly return.
PeriodHRTS
Year to date+9.8%
1 month+8.3%
3 months+6.4%
1 year+20.6%
3 yearsFund is under 3 years oldper yearNo data
5 yearsFund is under 5 years oldper yearNo data
10 yearsFund is under 10 years oldper yearNo data

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for HRTS
YearReturn barHRTS
2026 YTD+9.8%
2025+23.9%
2024−4.3%
2023+14.9%

History from Nov 21, 2023

HRTS in the news

HRTS Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Nov 2, 2026.
1.22%Last 12 months
Payout per share
$0.47Last 12 months
Last payment
$0.47 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Annual

Distribution history

2024–2026

One bar per payment. 2 payments from 2024 to 2026 YTD. Dec 11, 2024 $0.47; Dec 10, 2025 $0.47. Use the arrow keys to read each point.202420252026YTD
Ex-datePay dateAmount per share
Dec 10, 2025Dec 11, 2025$0.47
Dec 11, 2024Dec 12, 2024$0.47

$10,000 in HRTS 1 year ago paid $146 in dividends.

HRTS Risk

Risk pillarC52 out of 100Rank 12 of 25 in Health Care (Broad)
How much the fund’s monthly returns vary, scaled to a year.
17.7%
Annualised · 35 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.61
vs 3-month T-bills · 35 months to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−25.8%
35 months · trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.66
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

HRTS Cost

Compare HRTS and XLV

Overpaying vs XLV, cheapest in Health Care (Broad)

$12,793

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • HRTS 0.75%

    $14,482

  • XLV 0.08% Cheapest

    $1,689

$10,000
30 years

Cost over time

  • HRTS 0.75%
  • XLV 0.08%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$5K$10K$15K051015202530HRTS $14,482XLV $1,689

Year by year

YearHRTSXLVOverpaying
10$1,336$147$1,189
20$5,078$575$4,503
30$14,482$1,689$12,793
How the 0.75% is worked out

Full fee 0.99%− waiver 0.24%= you pay 0.75%

The waiver ends Jun 28, 2027. After that the fee is 0.99% unless Tema renews it. Source: prospectus, Jun 2026.

Other funds in Health Care (Broad)

See others